0 0.00151400454201359 0.00378501135503398 0.00378501135503398 -0.00189250567751706 -0.00454201362604092 -0.00529901589704771 -0.00378501135503412
Sign Up Today X
Thanks for submitting the form.
Stockreport

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data [Yahoo! Finance]

Evolus, Inc. (EOLS)  More Company Research Source: Yahoo! Finance
Last evolus, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
Presented at the 2024 SCALE Meeting, these results represent a significant milestone in the company's strategic expansion within the aesthetic device market. These promising results bolster the company's upcoming Premarket Approval Application (“PMA”) for the U.S. launch of Evolus's dermal filler lines. Evolus plans to submit the PMA applications for Evolysse Lift and Smooth within 90 days. Strategic Significance The addition of Evolysse fillers to the company's portfolio will perfectly complement Evolus' flagship neurotoxin Jeuveau, which claims to be the fastest growing neurotoxin in the United States for the past three years. Evolysse with Jeuveau is projected to increase Evolus' total addressable market by 78%. This expansion positions Evolus as a more formidable player in the aesthetics sector, catering to a broader range of consumer needs. The company in this regard emphasized the consistency of the U.S. study results with previous European trials, enhancing confidence [Read more]
IMPACT SNAPSHOT EVENT TIME: EOLS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
EOLS alerts
from News Quantified
EOLS
NEWS
EOLS
Earnings
EOLS
Analyst Actions
EOLS
SEC Filings
Stockreport

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data [Yahoo! Finance]

Evolus, Inc.  (EOLS) 
More Company Research Source: Yahoo! Finance
Last evolus, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
Presented at the 2024 SCALE Meeting, these results represent a significant milestone in the company's strategic expansion within the aesthetic device market. These promising results bolster the company's upcoming Premarket Approval Application (“PMA”) for the U.S. launch of Evolus's dermal filler lines. Evolus plans to submit the PMA applications for Evolysse Lift and Smooth within 90 days. Strategic Significance The addition of Evolysse fillers to the company's portfolio will perfectly complement Evolus' flagship neurotoxin Jeuveau, which claims to be the fastest growing neurotoxin in the United States for the past three years. Evolysse with Jeuveau is projected to increase Evolus' total addressable market by 78%. This expansion positions Evolus as a more formidable player in the aesthetics sector, catering to a broader range of consumer needs. The company in this regard emphasized the consistency of the U.S. study results with previous European trials, enhancing confidence [Read more]
IMPACT SNAPSHOT
EVENT TIME:
EOLS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS